Optio conducts business development interviews for a rare disease product valuation in conjunction with the 35th Annual J.P. Morgan Healthcare Conference.

January 2017 – Optio engages with industry thought leaders to obtain insights supporting the valuation of two prospective rare disease compounds. This valuation project created supporting research as a precursor to our client obtaining initial investment for compound acquisition or in-licensing.